Publications by authors named "Giulia Cacciari"
Article Synopsis
- This study aimed to understand the long-term gastrointestinal effects and gut-brain interaction disorders in patients hospitalized for COVID-19 compared to those without the infection.
- The analysis included data from 883 patients, revealing that gastrointestinal symptoms were more prevalent in COVID-19 patients during hospitalization, but by the 12-month follow-up, controls reported higher rates of constipation and hard stools.
- Additionally, COVID-19 patients showed a significantly higher prevalence of irritable bowel syndrome (IBS) compared to controls, with certain factors like allergies and medication usage being associated with IBS diagnosis.
Article Synopsis
- A study examined the prevalence of gastrointestinal (GI) symptoms in hospitalized COVID-19 patients compared to non-COVID patients, confirming that GI symptoms are more common in those with COVID-19 (59.7% vs. 43.2%).
- The study involved 2036 patients and used a specific questionnaire to assess GI symptoms at hospital admission and after one month.
- Key findings include a reduction in GI symptoms over time in COVID-19 patients, but persistent nausea was associated with factors like female sex, high body mass index, dyspnea, and elevated C-reactive protein levels.
To provide data regarding clinical presentation, pathological features, management, and response to different treatments of patients with type I gastric neuroendocrine tumors in stages 0-2A. The study design consist of an Italian multicentre, retrospective analysis of patients with type I gastric neuroendocrine tumors managed with different therapeutic approaches: surgery, endoscopic surveillance, endoscopic resection, or somatostatin analog therapy. Among the 97 patients included, 3 underwent surgery, 45 (46.
View Article and Find Full Text PDFCeliac disease (CD) is a small intestine immune-mediated disorder triggered by gluten ingestion in genetically predisposed patients. This condition can also affect many extraintestinal tissues, including the liver. We report a patient presenting with a marked increase of transaminases at diagnosis of CD.
View Article and Find Full Text PDFPurpose: Peptide receptor radionuclide therapy (PRRT) is a relatively new treatment modality for patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs). The aim of this study was to determine the time to progression of patients treated with PRRT and to identify the prognostic factors related to treatment response.
Methods: Patients with sporadic GEP NETs prospectively treated with PRRT were retrospectively analysed.